

## In vivo multiclonal transfer of *bla*<sub>KPC-3</sub> from *Klebsiella pneumoniae* to *Escherichia coli* in surgery patients

F. Gona<sup>1</sup>, F. Barbera<sup>1</sup>, A. C. Pasquariello<sup>1</sup>, P. Grossi<sup>2</sup>, B. Gridelli<sup>3</sup>, M. L. Mezzatesta<sup>4</sup>, C. Caio<sup>4</sup>, S. Stefani<sup>4</sup> and P. G. Conaldi<sup>1,5</sup>

1) Department of Laboratory Medicine and Advanced Biotechnologies, Mediterranean Institute for Transplantation and Advanced Specialized Therapies (ISMETT), Palermo, 2) Infectious & Tropical Diseases Unit, Department of Surgical & Morphological Sciences, Insubria University, Varese, 3) Mediterranean Institute for Transplantation and Advanced Specialized Therapies (ISMETT), Palermo, 4) Department of Bio-Medical Sciences, Section of Microbiology, University of Catania, Catania and 5) Unit of Regenerative Medicine and Biomedical Technologies, Ri.MED Foundation, Palermo, Italy

### Abstract

During active surveillance at the Mediterranean Institute for Transplantation and Advanced Specialized Therapies (ISMETT, Palermo, Italy) with the CARBA screening medium, five pairs of *Klebsiella pneumoniae* carbapenemase (KPC)-producing *K. pneumoniae* and *Escherichia coli* strains were isolated in each of five colonized patients. In each patient, lateral gene transfer was demonstrated by comparing *K. pneumoniae* and *E. coli* strains, both possessing KPC-3, Tn4401a and pKpQIL-IT elements. The isolates were found to be multiclonal by multilocus sequence typing (sequence type (ST) 512 related to ST258, and ST307 belonging to a clonal complex different from the habitual sequence clone ST258 isolated in Italy) and pulsed-field gel electrophoresis. The results of our study highlight the easy transfer of KPC among *Enterobacteriaceae* colonizing the human intestine, and the active and careful surveillance required to identify and prevent the spread of these multidrug-resistant microorganisms.

**Keywords:** Colonization, *Escherichia coli*, *Klebsiella pneumoniae*, KPC, ST307

**Original Submission:** 10 October 2013; **Revised Submission:** 24 January 2014; **Accepted:** 24 January 2014

Editor: R. Cantón

**Article published online:** 30 January 2014

*Clin Microbiol Infect*

**Corresponding author:** F. Gona, Department of Laboratory Medicine and Advanced Biotechnologies, ISMETT, Via Tricomi 5, 90127 Palermo, Italy  
**E-mail:** fgona@ismett.edu

Over the last 10 years, multidrug-resistant (MDR) Gram-negative *Enterobacteriaceae* has posed a substantial challenge to the treatment of nosocomial infections, worsening the outcome of hospitalized patients, particularly in those at high risk, such as organ transplant recipients and patients undergoing specialized surgery. In Italy, from 2009 to 2012, carbapenem-resistant *Klebsiella pneumoniae* diffusion rose from 2.2% to 19.4%, with a prevalence of *K. pneumoniae* carbapenemase (KPC) enzymes [1].

The diffusion of KPC-producing *K. pneumoniae* strains followed two different lines: (i) in the beginning, a unique clone, ST258, was isolated in a number of countries around the world; (ii) recently, new extensively drug-resistant clones have appeared, evidence of the dissemination, by horizontal transfer, of the mobile genetic elements carrying the *bla*<sub>KPC</sub> gene. In fact, KPC enzymes are codified by genes frequently located in the Tn4401, which is often carried on conjugative plasmids that vary in size and structure [2,3]. In Italy, the most frequent KPC-carrying plasmid is pKpQIL-IT [4]. The horizontal transferability of these elements, together with clonal expansion of these MDR organisms, poses complex challenges to containment programmes and the planning of correct therapies. In fact, infections sustained by MDR organisms harbouring *bla*<sub>KPC</sub> genes are associated with therapeutic failure and high mortality rates [5,6], particularly in high-risk patients.

In the light of this situation, an active search for KPC producers colonizing immunocompromised patients, and patients on the waiting list for transplant, is urgently required.

In May 2013, our institute, the Mediterranean Institute for Transplantation and Advanced Specialized Therapies (ISMETT), following an active rectal swab surveillance programme with chromID<sup>®</sup> CARBA agar (bio-Mérieux Clinical Diagnostics, Marcy l'Étoile, France), five pairs of KPC-producing *K. pneumoniae* (KPC *Kp*) and *Escherichia coli* (KPC *Ec*) strains were isolated from each of five patients (two who underwent organ transplantation, and three who underwent cardiac surgery). At admission, these patients were colonized with KPC *Kp*, and two developed bloodstream infection with KPC *Kp*.

All rectal swabs at admission were inoculated on chromID<sup>®</sup> CARBA agar, and the suspected colonies with a pink/brown colour were identified and tested for antibiotic susceptibility with the BD Phoenix<sup>™</sup> Automated Microbiology System,

**TABLE 1.** Typing characterization of isolates by pulsed-field gel electrophoresis (PFGE) and multilocus sequence type (MLST)

Patients	Species	PFGE	ST
426814	<i>Escherichia coli</i>	A	131
426814	<i>Klebsiella pneumoniae</i>	B	512
427835	<i>E. coli</i>	B	1672
427835	<i>K. pneumoniae</i>	B	512
427862	<i>E. coli</i>	B	1672
427862	<i>K. pneumoniae</i>	B	512
426010	<i>E. coli</i>	B	1672
426010	<i>K. pneumoniae</i>	A	307
429422	<i>E. coli</i>	C	394
429422	<i>K. pneumoniae</i>	A	307

(Becton Dickinson, Franklin Lakes, NJ). Susceptibility results of all the strains were confirmed for imipenem, meropenem and ertapenem by both microdilution and gradient test methods (bio-Mérieux). MIC breakpoints were interpreted according to the European Committee on Antimicrobial Susceptibility Testing guidelines [7]. All isolates were confirmed by phenotypic testing for carbapenemase with aminophenyl boronic acid and dipicolinic acid (Rosco Diagnostica, Taastrup, Denmark). The results of the phenotypic confirmation test were all positive for KPC. The resistant determinants (*bla*<sub>KPC</sub> and extended spectrum  $\beta$ -lactamase-encoding genes), and the localization of *bla*<sub>KPC</sub> (Tn4401 and plasmid), were revealed by PCR assay, using previously described primers [3].

Conjugation experiments were carried out on *E. coli* J-53 as recipient and the transconjugants were selected with meropenem (4 mg/L) and rifampicin (300 mg/L). The identification of  $\beta$ -lactamase genes was performed by PCR [8]. No transconjugants were obtained. In particular, the transconjugant obtained with *K. pneumoniae* n. 429422 and *E. coli* J-53 showed a very slight growth, insufficient for molecular verification, so we could not determine conjugation.

Typing characterizations were performed by using pulsed-field gel electrophoresis and multilocus sequence typing, as previously described [9,10].

The five strains of *E. coli* and *K. pneumoniae* presented multiclonal macrorestriction profiles by pulsed-field gel electrophoresis, performed after *Xba*I digestion [11]. The pulsed-field gel electrophoresis clones coincided with sequence types (STs) found by multilocus sequence typing (Table 1).

In *E. coli*, three pulsed field gel electrophoresis clones and three different STs were found: clone A was ST131, clone B was ST1672, and clone C was ST394 [12]. The two pulsotypes of *K. pneumoniae* (type A in two strains, and type B in three strains) coincided with sequence types (STs) (clone A ST512 and clone B ST307) [12]. In particular, clone ST512 is a single locus variant of ST258, already found in other Italian hospitals [13], whereas there is no information on the presence of *K. pneumoniae* ST307 in Italy.

Table 1 also shows the  $\beta$ -lactamase-encoding genes of the isolates. All strains were confirmed to harbour the *bla*<sub>KPC-3</sub> and the *bla*<sub>TEM-1</sub> genes. The only KPC *Ec* frankly resistant also contained *bla*<sub>CTX-M-15</sub>. The same genes were found in the co-cultured *K. pneumoniae* of the same patient. Plasmid analysis was performed using extraction (QIAGEN Plasmid Mini Kit; Qiagen, Les Ulis, France) and direct sequencing (3500 Genetic Analyzer; Applied Biosystems, Carlsbad, CA), and revealed that *bla*<sub>KPC-3</sub> genes were in all cases embedded in a Tn4401a transposon, and plasmid sequences matched for the presence of the pKpQIL-IT in all strains under study [14].

*Escherichia coli* ST394 was previously not a KPC producer but harboured extended spectrum  $\beta$ -lactamase genes (*bla*<sub>CTX-M-15</sub> and *bla*<sub>TEM-1</sub>); after 2 weeks the same clone was isolated and was a KPC producer.

Among patients nos 427835, 427862 and 426010, KPC-3-producing *E. coli* was acquired by cross-transmission

**TABLE 2.** Susceptibility to carbapenems measured by three methods of *Klebsiella pneumoniae* carbapenemase (KPC)-producing strains

Patients	Species	Isolation date	MICs of carbapenems (mg/L)								
			Ertapenem BP (0.5/1)			Meropenem BP (2/8)			Imipenem BP (2/8)		
			Ph	BMD	Gradient test	Ph	BMD	Gradient test	Ph	BMD	Gradient test
426814	<i>Escherichia coli</i>	5/3/2013	>1	1	0.75	≤1	0.5	2	≤1	0.5	8
	<i>K. pneumoniae</i>		>1	128	>32	>8	>32	>32	>8	>32	>32
427835	<i>E. coli</i>	5/10/2013	>1	4	1.5	≤1	1	0.75	4	1	3
	<i>K. pneumoniae</i>		>1	128	>32	>8	>32	>32	>8	64	>32
427862	<i>E. coli</i>	5/15/2013	>1	4	2	≤1	4	2	4	1	4
	<i>K. pneumoniae</i>		>1	128	>32	>8	64	>32	>8	64	>32
426010	<i>E. coli</i>	4/30/2013	>1	1	1.5	≤1	2	0.75	4	0.5	3.1
	<i>K. pneumoniae</i>		>1	128	>32	>8	256	>32	>8	256	>32
429422	<i>E. coli</i>	4/27/2013	<1	0.12	0.25	<1	0.12	0.06	<1	0.12	0.12
	<i>K. pneumoniae</i>		>1	128	>32	>8	512	>32	>8	512	>32
	<i>E. coli</i>	5/11/2013	>1	>128	>32	>8	128	32	>8	64	32
	<i>K. pneumoniae</i>		>1	128	>32	>8	512	>32	>8	512	>32

Ph, Phoenix; BMD, microdilution broth; BP, breakpoint.

during hospitalization in the same ward. The route of acquisition of both KPC producer strains is undetermined for patient no. 426814 because he was positive at the admission date and, moreover, the strain belonged to a different clone (ST131). Table 2 summarizes the susceptibility testing of all isolates. All *K. pneumoniae* strains were resistant to all carbapenems with all methods used, whereas KPC *Ec*, possessed lower MIC values compared with those observed in *K. pneumoniae*. In the KPC *Ec* strains, the automated Phoenix system showed reduced susceptibility values to meropenem and imipenem, with the sole exception of one isolate, fully resistant to the three carbapenems with all methods. In the other four strains, all susceptible by the Phoenix system, gradient testing revealed a reduced susceptibility to carbapenems, with the exception of ertapenem, which showed a resistant or intermediate level with all methods used. In the light of these findings, this drug was used as the marker of resistance.

Our paper highlights the simple, and worrisome, *in vivo* inter-species transfer of pKpQIL-IT containing the *bla*<sub>KPC</sub> gene. This event can be underappreciated and underreported because of the low expression level of this resistance determinant in a genetic background different from *K. pneumoniae*, as already observed [15]. Even if little is known about the role that gene expression plays in KPC-mediated resistance, or how the level of expression may affect susceptibility testing, several hypotheses have emerged: (i) some studies have reported a possible presence of different isoforms of Tn4401 with different upstream promoters involved in different degrees of expression [14]; (ii) the KPC gene can be located in a low number of plasmid copies, as reported in previous studies [15]. Further studies will be necessary to fully understand this low level of expression in KPC *Ec*.

The ease of *in vivo* transfer of KPC between *K. pneumoniae* and *E. coli* is extremely worrisome, and our study strengthens the importance of infection control measures for rapid detection of KPC in nosocomial pathogens, in order to prevent further dissemination and, in case of infection, provide direct targeted therapy.

## Acknowledgements

We thank Ornella Campanella for her active support in infection control at ISMETT.

## Transparency Declaration

This work was partially supported by research grants from the Region Sicily (POR FESR Sicilia 2007–2013, SIASOPs BioBank

CUP G83F11000290004), from the Ri.MED Foundation, and from the Fondazione Banco di Sicilia (to F.B.) None of the authors have a commercial interest or other association that might pose a conflict of interest.

## References

1. Sisto A, D'Ancona F, Meledandri M *et al*. Carbapenem non-susceptible *Klebsiella pneumoniae* from Micronet network hospitals, Italy, 2009 to 2012. *Euro Surveill* 2012; 17: 20247.
2. Naas T, Cuzon G, Villegas MV, Lartigue MF, Quinn JP, Nordmann P. Genetic structures at the origin of acquisition of the  $\beta$ -lactamase blaKPC gene. *Antimicrob Agents Chemother* 2008; 52: 1257–1263.
3. Mezzatesta ML, Gona F, Caio C *et al*. Emergence of an extensively drug-resistant ArmA and KPC-2-producing ST101 *Klebsiella pneumoniae* clone in Italy. *J Antimicrob Chemother* 2013; 68: 1932–1934.
4. García-Fernández A, Villa L, Carta C *et al*. *Klebsiella pneumoniae* ST258 producing KPC-3 identified in Italy carries novel plasmids and OmpK36/OmpK35 porin variants. *Antimicrob Agents Chemother* 2012; 56: 2143–2145.
5. Kalpoe JS, Sonnenberg E, Factor SH *et al*. Mortality associated with carbapenem-resistant *Klebsiella pneumoniae* infections in liver transplant recipients. *Liver Transpl* 2012; 18: 468–474.
6. Bergamasco MD, Barroso Barbosa M, de Oliveira Garcia D *et al*. Infection with *Klebsiella pneumoniae* carbapenemase (KPC)-producing *K. pneumoniae* in solid organ transplantation. *Transpl Infect Dis* 2012; 14: 198–205.
7. The European Committee on Antimicrobial Susceptibility Testing. *Breakpoint tables for interpretation of MICs and zone diameters. Version 3.1*. Basel, Switzerland: EUCAST, 2013.
8. Perilli M, Bottoni C, Grimaldi A *et al*. Carbapenem-resistant *Klebsiella pneumoniae* harbouring blaKPC-3 and blaVIM-2 from central Italy. *Diagn Microbiol Infect Dis* 2013; 75: 218–221.
9. Mezzatesta ML, Gona F, Caio C *et al*. Outbreak of KPC-3-producing, and colistin-resistant, *Klebsiella pneumoniae* infections in two Sicilian hospitals. *Clin Microbiol Infect* 2011; 17: 1444–1447.
10. Diancourt L, Passet V, Verhoef J, Grimont PA, Brisse S. Multilocus sequence typing of *Klebsiella pneumoniae* nosocomial isolates. *J Clin Microbiol* 2005; 43: 4178–4182.
11. Tenover FC, Arbeit RD, Goering RV *et al*. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis criteria for bacterial strain typing. *J Clin Microbiol* 1995; 33: 2233–2239.
12. Wirth T, Falush D, Lan R *et al*. Sex and virulence in *Escherichia coli*: an evolutionary perspective. *Mol Microbiol* 2006; 60: 1136–1151.
13. Ceccarelli G, Falcone M, Giordano A *et al*. Successful ertapenem-doripenem combination treatment of bacteremic ventilator-associated pneumonia due to colistin-resistant KPC-producing *Klebsiella pneumoniae*. *Antimicrob Agents Chemother* 2013; 57: 2900–2901.
14. Naas T, Cuzon G, Truong HV, Nordmann P. Role of ISKpn7 and deletions in blaKPC gene expression. *Antimicrob Agents Chemother* 2012; 56: 4753–4759.
15. Roth AL, Kurpiel PM, Lister PD, Hanson ND. blaKPC RNA expression correlates with two transcriptional start sites but not always with gene copy number in four genera of Gram-negative pathogens. *Antimicrob Agents Chemother* 2011; 55: 3936–3938.